Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenal Gland Disorders

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Shining Light on Dysautonomia: The Role of Vitamin D in Cardiac Autonomic Regulation.

Current nutrition reports·2026

Same author

Impact of continuous positive airway pressure therapy on renin-angiotensin-aldosterone system in obstructive sleep apnea: an updated systematic review and meta-analysis.

Sleep & breathing = Schlaf & Atmung·2026

Same author

Predictors of vitamin D deficiency and quality of life in obese patients with obstructive sleep apnea.

Scientific reports·2026

Same author

Prevalence of Hypogonadism Among Males with Type 2 Diabetes Mellitus in a Malaysian Tertiary Hospital: A Cross-Sectional Study.

Journal of the ASEAN Federation of Endocrine Societies·2025

Same author

Cardiac Autonomic Dysfunction in Obstructive Sleep Apnea: The Hidden Role of Vitamin D Deficiency.

Journal of evidence-based medicine·2025

Same author

"Tamoxifen for residual NF-PitNETs: A Proof-of-Concept study integrating receptor profiling, pilot trial, and target pathway analysis".

Endocrine·2025

Search research articles

Related Experiment Videos

Primary aldosteronism: from bench to bedside.

Norlela Sukor¹

¹Endocrine Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia. drlela2020@yahoo.com

|November 2, 2011

Summary

This summary is machine-generated.

Primary aldosteronism, a common cause of hypertension, is curable and treatable. Early detection and management are crucial to prevent cardiovascular events and organ damage beyond blood pressure control.

Related Experiment Videos

Area of Science:

Endocrinology
Cardiology
Nephrology

Background:

Primary aldosteronism is the most common cause of secondary hypertension, often curable and treatable.
Patients with primary aldosteronism face higher risks of cardiovascular events and target organ damage compared to essential hypertensives.
Current treatment goals extend beyond blood pressure and potassium normalization to address aldosterone-induced tissue damage.

Purpose of the Study:

To provide a comprehensive review of the current understanding of primary aldosteronism.
To highlight recent evidence and advancements in the management of primary aldosteronism.
To emphasize the importance of targeted treatment for improved patient outcomes.

Main Methods:

Literature review of recent studies and clinical guidelines.
Analysis of evidence regarding diagnosis and treatment strategies.
Synthesis of current knowledge on pathophysiology and clinical implications.

Main Results:

Primary aldosteronism is a significant contributor to hypertension-related morbidity.
Effective management requires addressing aldosterone excess beyond blood pressure control.
New evidence underscores the necessity of mineralocorticoid blockade for preventing tissue damage.

Conclusions:

Early detection and comprehensive management of primary aldosteronism are critical for preventing cardiovascular complications.
Treatment should focus on normalizing aldosterone levels or blockade to mitigate aldosterone-specific tissue damage.
This review synthesizes recent findings to guide optimal clinical practice for primary aldosteronism.